Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q3 FY21 results · Oct–Dec 2020
Panacea Biotec reported revenue from operations of ₹141.76 crore (down 15.5% from Q3 FY20) and net loss of ₹40.05 crore for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 141.76 | 167.74 | −15.5% | 182.02 | −22.1% |
| Other income | 1.89 | 3.23 | −41.5% | 2.00 | −5.5% |
| Total income | 143.65 | 170.97 | −16.0% | 184.02 | −21.9% |
| Profit before share of associates & JVs and tax | (39.96) | (17.90) | Loss widened | (18.88) | Loss widened |
| Share of profit/(loss) of associates & JVs | (0.05) | 0.07 | 0.07 | ||
| Net profit for the period | (40.05) | (21.32) | Loss widened | (19.33) | Loss widened |
| EPS, basic (₹) | (6.54) | (3.48) | Loss widened | (3.16) | Loss widened |
| Net margin (%) | -28.3 | -12.7 | -10.6 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 69.02 | 55.52 | +24.3% | 118.20 | −41.6% |
| Other income | 7.17 | 1.16 | +518.1% | 2.95 | +143.1% |
| Total income | 76.19 | 56.68 | +34.4% | 121.15 | −37.1% |
| Profit before tax | 1.91 | 1.05 | +81.9% | 10.13 | −81.1% |
| Net profit for the period | 1.90 | (19.74) | Turned profit | 10.81 | −82.4% |
| EPS, basic (₹) | 0.31 | (3.23) | Turned profit | 1.76 | −82.4% |
| Net margin (%) | 2.8 | -35.6 | 9.1 |
Consolidated
- Filed with BSE
- 12 Feb 2021, 18:57 IST
- Board meeting
- 12 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Feb 2021, 18:57 IST
- Board meeting
- 12 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE